Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 14/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.48 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.47 |
| ▸ | THRA | P10827 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13441805 | 0.89 | PTGDR2 (0.51) | PTGDR2TDP1MAPTSLC6A9THRA | |
| SCHEMBL7475116 | 0.81 | PTGDR2 (0.68) | PTGDR2TDP1SLC6A9PTGDR | |
| SCHEMBL14419260 | 0.80 | TDP1 (0.52) | PTGDR2TDP1MAPTTSHRPTGDR | |
| SCHEMBL21056958 | 0.79 | TSHR (0.54) | PTGDR2TSHRSLC6A9PTGDR | |
| SCHEMBL21056961 | 0.79 | TSHR (0.54) | PTGDR2TSHRSLC6A9PTGDR | |
| SCHEMBL28120090 | 0.77 | KCNMA1 (0.53) | TDP1 | |
| SCHEMBL12147488 | 0.77 | PTGDR2 (0.76) | PTGDR2TDP1MAPTTSHRPTGDR | |
| SCHEMBL1106995 | 0.76 | KCNMA1 (0.47) | PTGDR2MAPTPTGDR | |
| SCHEMBL1753654 | 0.76 | PTGDR2 (0.85) | PTGDR2TDP1MAPTTSHRPTGDR | |
| SCHEMBL12147402 | 0.75 | PTGDR2 (0.68) | PTGDR2TDP1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385028-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2019-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385028-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | PTGDR2 2581/4885TDP1 277/4885MAPT 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.